Established in 2010, this Israeli based medical device company is implementing a novel approach to using Diffusion Weighted MRI technology for assessment of tissue in cancer surgery. The highly accurate system is compact, portable and affordable for use in the operating room for real-time assessment of the excised tissue for cancer. Breast cancer conserving surgery will be the initial target procedure where between 25% to 30% of the nearly 700,000 annual patients return for a second operation due to not excising adequate tissue for a clean margin.
The system was CE Mark certified in September 2014 and an FDA 510(k) application is planned to be submitted by mid 2015. Commercialization is planned for early 2016. The company management is comprised of an experienced team with prior success in the medical device field. The system consists of the self-shielded portable MRI system and a single patient container made of high tolerance MRI-inert materials; thus providing multiple revenue stream options. The Series B Preferred offering is seeking funding with minimal investment of $200k per investor.
Startup Israeli medical device company seeking Series B funding for novel tissue MRI for cancer surgery
